Toward in vivo targeting delivery of siRNA for efficient cancer therapy

O. Taratula, P. Kirkpatrick, R. Savla, I. Pandya, T. Minko, H. He

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The main obstacle in siRNA therapy is RNA delivery to the cytoplasm, where it can guide sequence-specific mRNA degradation. Attempts to develop effective nonviral vectors for in vivo delivery of nucleic acids through a systemic route are hampered by difficulties of combining high extracellular stability with ready availability of the nucleic acids following entry into cells. Other challenges with non-viral gene delivery include limitations in target-cell specificity. Here we report a targeted siRNA delivery vector that displays good extracellular stability and intracellular bioavailability to permit efficient gene silencing.

Original languageEnglish (US)
Title of host publicationTechnical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008
Pages346-349
Number of pages4
StatePublished - 2008
Event2008 NSTI Nanotechnology Conference and Trade Show, NSTI Nanotech 2008 Joint Meeting, Nanotechnology 2008 - Quebec City, QC, United States
Duration: Jun 1 2008Jun 5 2008

Publication series

NameTechnical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008
Volume2

Other

Other2008 NSTI Nanotechnology Conference and Trade Show, NSTI Nanotech 2008 Joint Meeting, Nanotechnology 2008
Country/TerritoryUnited States
CityQuebec City, QC
Period6/1/086/5/08

All Science Journal Classification (ASJC) codes

  • Mechanical Engineering

Keywords

  • Dendrimers
  • PPI
  • Poly(propyleneimine)
  • Targeted delivery
  • siRNA

Fingerprint

Dive into the research topics of 'Toward in vivo targeting delivery of siRNA for efficient cancer therapy'. Together they form a unique fingerprint.

Cite this